会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 4. 发明授权
    • Method for synthesizing DNA
    • DNA合成方法
    • US06673578B1
    • 2004-01-06
    • US09786684
    • 2001-05-22
    • Takashi UemoriYoshimi SatoMariko OkawaTomoko FujitaKazue MiyakeOsamu TakedaHiroaki SagawaMichio HagiyaHiroyuki MukaiKiyozo AsadaIkunoshin Kato
    • Takashi UemoriYoshimi SatoMariko OkawaTomoko FujitaKazue MiyakeOsamu TakedaHiroaki SagawaMichio HagiyaHiroyuki MukaiKiyozo AsadaIkunoshin Kato
    • C12P1934
    • C12N15/1003C12Q1/686C12Q2527/125
    • A DNA synthesis method with a shortened time period required for DNA synthesis by polymerase chain reaction (PCR), characterized in that a DNA polymerase is used in an amount effective for providing more than 10 ng of amplified DNA fragments of about 2 kb per 50 &mgr;l of a reaction mixture, when PCR is carried out under the following conditions (A) and (B): (A) reaction mixture: 50 &mgr;l volume of a reaction mixture comprising DNA polymerase, 1 ng of genomic DNA from Escherichia coli, and 10 pmol each of primers Eco-1 and Eco-2 (nucleotide sequences of the primers Eco-1 and Eco-2 being shown in SEQ ID NOs: 10 and 11 of Sequence Listing, respectively); and having a composition suitable for the DNA polymerase; and (B) reaction conditions: 35 cycles of PCR, wherein one cycle consists of 99° C., 1 second-66° C., 7 seconds; a kit for DNA synthesis usable for the DNA synthesis method; and an article of manufacture of a PCR agent. According to the present invention, the procedures in the genetic engineering studies and industries involved with PCR can be speeded up.
    • 一种DNA合成方法,其通过聚合酶链式反应(PCR)进行DNA合成所需的时间缩短,其特征在于使用DNA聚合酶,其量有效提供超过10ng每50ul约2kb的扩增DNA片段 的反应混合物,当在以下条件(A)和(B)下进行PCR时:(A)反应混合物:将50体积的包含DNA聚合酶的反应混合物,1ng来自大肠杆菌的基因组DNA和10ng 各引物Eco-1和Eco-2(引物Eco-1和Eco-2的核苷酸序列分别示于序列表的SEQ ID NO:10和11中) 并具有适合于DNA聚合酶的组合物; 和(B)反应条件:35个循环的PCR,其中一个循环由99℃,1秒-66℃,7秒; 用于DNA合成方法的DNA合成试剂盒; 以及PCR试剂的制造。 根据本发明,可以加快基因工程研究和涉及PCR的行业的程序。
    • 10. 发明授权
    • Therapeutic agents
    • 治疗剂
    • US06531148B1
    • 2003-03-11
    • US09719314
    • 2001-02-01
    • Tatsuji EnokiJun TomonoNobuto KoyamaKatsushige IkaiHiroaki SagawaIkunoshin Kato
    • Tatsuji EnokiJun TomonoNobuto KoyamaKatsushige IkaiHiroaki SagawaIkunoshin Kato
    • A61K4700
    • A61K31/7004A23L3/3535A23L3/3562A23L33/10A23V2002/00A61K31/35A61K31/351A61K31/357A23V2250/60A23V2250/608A23V2250/5024A23V2250/5036
    • Therapeutic or preventive agents for diseases requiring apoptosis induction, cancerous diseases, diseases requiring the inhibition of active oxygen production, those requiring the inhibition of nitrogen monoxide production, those requiring the inhibition of prostaglandin synthesis, those requiring the inhibition of synovial cell proliferation, those requiring the induction of heat shock protein production or those requiring the inhibition of &agr;-glycosidase, which contain as the active ingredient compounds selected from among compounds represented by general formula (I), (wherein X and Y are each H or CH2OH, provided that when X is CH2OH, Y is H, while when X is H, Y is CH2OH), those represented by general formula (II), (wherein R is a residue obtained by freeing a compound having an SH group from the SH group) and salts of both; and foods, drinks, cosmetics and so on, containing compounds selected from among compounds of general formula (I), those of general formula (II) and salts of both.
    • 需要细胞凋亡诱导的疾病,癌性疾病,需要抑制活性氧产生的疾病,需要抑制一氧化氮生成的那些的治疗或预防剂,需要抑制前列腺素合成的那些,需要抑制滑膜细胞增殖的那些,需要 诱导热休克蛋白产生或需要抑制α-糖苷酶的那些,其含有选自通式(I)表示的化合物中的活性成分,其中X和Y各自为H或CH 2 OH,条件是当 X是CH 2 OH,Y是H,而X是H,Y是CH 2 OH),由通式(II)表示的那些(其中R是从SH基团中释放具有SH基团的化合物获得的残基) 的两个 和食品,饮料,化妆品等,其含有选自通式(I)的化合物,通式(II)的化合物和二者的盐的化合物。